Bernstein Liebhard LLP Reports On Study That Finds FDA Too Quick To Approve New Drugs
Bernstein Liebhard LLP, a nationwide law firm representing clients who experienced complications from dangerous drugs such as Fosamax, reports on a May 16, 2012 study published in The New England Journal of Medicine (“NEJM”) that found that the U.S. Food and Drug Administration (“FDA”) approved more new drugs quicker than its European and Canadian counterparts in the last decade. The study found that from 2001 to 2010, the FDA approved 225 new drugs, while the European Medicines Agency (“EMA”) approved 186, and Health Canada approved 99. The study also found that most new drugs are approved in the U.S. faster than in the other two regions. Given that the majority of these new drugs only go through just one review cycle by the FDA, they received market approval in the U.S. earlier than in Europe and Canada. Specifically, researchers found that the FDA approved 64 percent of newly introduced drugs before the EMA, and 86 percent of drugs before Health Canada. This analysis is the first to compare the FDA’s drug review performance to other health regulatory agencies around the world.
Fosamax Complications Might Have Been Detected With A Thorough Review
Bernstein Liebhard LLP is concerned about the consequences of the FDA’s speedy approval process, which may have led to the approval of dangerous drugs like Fosamax. In 1995, Merck received FDA approval for Fosamax without having performed any long-term safety testing. Since then, Fosamax has been linked to several severe side effects such as osteonecrosis of the jaw and atypical femur fractures. Many believe that Fosamax complications, such as femur fractures could have been detected sooner if the FDA had conducted a thorough review. A May 9, 2012 FDA analysis published in NJEM cautioned against the long-term use of Fosamax due to its limited benefit and potential complications.
Fosamax Femur Fracture Injuries At The Center Of Litigation
Individuals who have experienced Fosamax complications such as atypical femur fractures are filing lawsuits against the drug’s manufacturer. The lawyers at Bernstein Liebhard LLP are actively filing cases on behalf of these individuals in the Superior Court of New Jersey, Atlantic County in In re: Fosamax Litigation (No. 282 N.J. Super. Ct.). Those who took Fosamax and sustained a femur fracture may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. Learn more by watching this Fosamax femur fracture video, or by visiting our website, www.consumerinjurylawyers.com.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 (877) 779-1414
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.